Dynamics Within Industry-Academia Partnerships Changing - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cancer Drug News Issue 666" report to their offering.

The favourable terms for academia in the deal highlight a shift in dynamics in industry-academia partnership. As more big pharma companies seek to leverage open innovation to drive lower cost, faster and more flexible R&D, competition for top institutions will increase. We expect a move away from academia being seen as just a provider of early research for the industry, towards more equally weighted partnerships.

Key Topics Covered:

1. Dynamics Within Industry-Academia Partnerships Changing
2. CHMP Adopts Positive Opinion On Empliciti For MM
3. Kyprolis Approved For Multiple Myeloma In Canada
4. Bendeka Available In US
5. Venetoclax Receives FDA Breakthrough Therapy Designation For AML
6. Cabozantinib Will Encounter Toughening Market Environment Despite Swift Entry
7. Tookad Filed For Approval In Mexico Following Positive Phase III Results In PCA
8. AstraZeneca's Lynparza Drive Will Secure Sustained Revenue Growth
9. Stelba Submits Tookad MAA To EMA
10. Jakafi Phase II Substudy Stopped Early Due To Insufficient Efficacy
11. Halozyme Raises Funds To Continue Oncology Development
12. Sun Launches Imatinib Mesylate In US
13. HUYA Grants Exclusive Licence For HBI-8000 To Eisai
14. Aduro Receives Clinical Development Milestone Payments From Janssen
15. FDA Approves Eisai's Halaven For Advanced Liposarcoma
16. Adicet Raises Funds; Acquires Applied Immune Technologies
17. Spectrum Initiates SPI-2012 Phase III Trial Chemotherapy-Induced Neutropenia In BC
18. Strong Oncology Profile To Support 2016 Growth
    

For more information visit http://www.researchandmarkets.com/research/mkptcr/cancer_drug_news